Serum concentrations of pegylated interferon α-2b in patients with resected stage III melanoma receiving adjuvant pegylated interferon α-2b in a randomized phase III trial (EORTC 18991)

Cancer Chemotherapy and Pharmacology

Volumn 65, Issue 4, 2010, Pages 671-677

  Eggermont, Alexander M M ^a   Bouwhuis, Marna G ^a   Kruit, Wim H ^a   Testori, Alessandro ^b   Ten Hagen, Timo ^a   Yver, Antoine ^c   Xu, Christine ^c  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Cytokines; Melanoma; Peginterferon alfa 2b; Pharmacokinetics

Indexed keywords

PEGINTERFERON ALPHA2B; ALPHA2B INTERFERON; MACROGOL DERIVATIVE; PEGINTERFERON ALFA-2B;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LONG TERM CARE; MALE; MELANOMA; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TREATMENT DURATION; ADJUVANT CHEMOTHERAPY; BLOOD; DOSE RESPONSE; DRUG ADMINISTRATION; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; TIME; TREATMENT OUTCOME;

ADULT; AGED; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INTERFERON ALFA-2B; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; POLYETHYLENE GLYCOLS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 75749126964     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-1072-z     Document Type: Article

References (28)

1. A Jemal R Siegel E Ward T Murray J Xu MJ Thun 2007 Cancer statistics, 2007 CA Cancer J Clin 57 43 66 10.3322/canjclin.57.1.43 17237035
2. AM Eggermont JM Kirkwood 2004 Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur J Cancer 40 1825 1836 10.1016/j.ejca.2004.04.030 1:CAS:528:DC%2BD2cXmt1OitL0%3D 15288283 (Pubitemid 39036756)
3. CM Balch SJ Soong JE Gershenwald JF Thompson DS Reintgen N Cascinelli M Urist KM McMasters MI Ross JM Kirkwood MB Atkins JA Thompson DG Coit D Byrd R Desmond Y Zhang PY Liu GH Lyman A Morabito 2001 Prognostic factors analysis of 17, 600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system J Clin Oncol 19 3622 3634 1:STN:280: DC%2BD3MvlvV2ktA%3D%3D 11504744
4. F Belardelli M Ferrantini E Proietti JM Kirkwood 2002 Interferon-alpha in tumor immunity and immunotherapy Cytokine Growth Factor Rev 13 119 134 10.1016/S1359-6101(01)00022-3 1:CAS:528:DC%2BD38XitFWhsrk%3D 11900988 (Pubitemid 34229387)
5. JM Kirkwood MH Strawderman MS Ernstoff TJ Smith EC Borden RH Blum 1996 Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684 J Clin Oncol 14 7 17 1:CAS:528:DyaK28XhtVOjtrk%3D 8558223
6. JM Kirkwood JG Ibrahim VK Sondak J Richards LE Flaherty MS Ernstoff TJ Smith U Rao M Steele RH Blum 2000 High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190 J Clin Oncol 18 2444 2458 1:CAS:528:DC%2BD3cXkvFWrsbo%3D 10856105
7. JM Kirkwood JG Ibrahim JA Sosman VK Sondak SS Agarwala MS Ernstoff U Rao 2001 High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801 J Clin Oncol 19 2370 2380 1:CAS:528:DC%2BD3MXjvVeltbg%3D 11331315
8. K Wheatley N Ives B Hancock M Gore A Eggermont S Suciu 2003 Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials Cancer Treat Rev 29 241 252 10.1016/S0305-7372(03)00074-4 1:CAS:528:DC%2BD3sXmsVCns7s%3D 12927565 (Pubitemid 37069655)
9. JM Kirkwood J Manola J Ibrahim V Sondak MS Ernstoff U Rao 2004 A pooled analysis of Eastern Cooperative Oncology Group and intergroup trials of adjuvant high-dose interferon for melanoma Clin Cancer Res 10 1670 1677 10.1158/1078-0432.CCR-1103-3 1:CAS:528:DC%2BD2cXhvFCltr4%3D 15014018 (Pubitemid 38435557)
10. LM Schuchter 2004 Adjuvant interferon therapy for melanoma: high-dose, low-dose, no dose, which dose? J Clin Oncol 22 7 10 10.1200/JCO.2004.10.907 1:CAS:528:DC%2BD2cXpsVKitb0%3D 14665612 (Pubitemid 41095106)
11. YS Wang S Youngster J Bausch R Zhang C McNemar DF Wyss 2000 Identification of the major positional isomer of pegylated interferon alpha-2b Biochemistry 39 10634 10640 10.1021/bi000617t 1:CAS:528:DC%2BD3cXlsVShurY%3D 10978146 (Pubitemid 30682771)
12. K Vyas DL Brassard MM DeLorenzo Y Sun MJ Grace EC Borden DW Leaman 2003 Biologic activity of polyethylene glycol12000-interferon-alpha2b compared with interferon-alpha2b: gene modulatory and antigrowth effects in tumor cells J Immunother 26 202 211 10.1097/00002371-200305000-00004 1:CAS:528: DC%2BD3sXksVOnu70%3D 12806274 (Pubitemid 36686889)
13. P Glue JW Fang R Rouzier-Panis C Raffanel R Sabo SK Gupta M Salfi S Jacobs 2000 Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group Clin Pharmacol Ther 68 556 567 10.1067/mcp.2000.110973 1:CAS:528: DC%2BD3cXovVeru78%3D 11103758 (Pubitemid 30953875)
14. RM Bukowski C Tendler D Cutler E Rose MM Laughlin P Statkevich 2002 Treating cancer with PEG intron: pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation Cancer 95 389 396 10.1002/cncr.10663 1:CAS:528:DC%2BD38Xmt1ehtbs%3D 12124839 (Pubitemid 34787605)
15. KL Lindsay C Trepo T Heintges ML Shiffman SC Gordon JC Hoefs ER Schiff ZD Goodman M Laughlin R Yao JK Albrecht 2001 A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C Hepatology 34 395 403 10.1053/jhep.2001.26371 1:CAS:528:DC%2BD3MXmtVGqtLs%3D 11481625 (Pubitemid 32702353)
16. MJ Grace DL Cutler RW Bordens 2005 Pegylated IFNs for chronic hepatitis C: an update Expert Opin Drug Deliv 2 219 226 10.1517/17425247.2.2.219 1:CAS:528:DC%2BD2MXjsFansbc%3D 16296749 (Pubitemid 41130879)
17. M Silva J Poo F Wagner M Jackson D Cutler M Grace R Bordens C Cullen J Harvey M Laughlin 2006 A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE) J Hepatol 45 204 213 10.1016/j.jhep.2006.03.008 1:CAS:528:DC%2BD28Xmslylur0%3D 16780997
18. M Talpaz S O'Brien E Rose S Gupta J Shan J Cortes FJ Giles S Faderl HM Kantarjian 2001 Phase 1 study of polyethylene glycol formulation of interferon alpha-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia Blood 98 1708 1713 10.1182/blood.V98.6.1708 1:CAS:528:DC%2BD3MXntFWgsLc%3D 11535501
19. R Bukowski MS Ernstoff ME Gore JJ Nemunaitis R Amato SK Gupta CL Tendler 2002 Pegylated interferon alfa-2b treatment for patients with solid tumors: a phase I/II study J Clin Oncol 20 3841 3849 10.1200/JCO.2002.02.051 1:CAS:528:DC%2BD38XntVyns7k%3D 12228203 (Pubitemid 35050837)
20. AM Eggermont S Suciu M Santinami A Testori WH Kruit J Marsden CJ Punt F Sales M Gore R Mackie Z Kusic R Dummer A Hauschild E Musat A Spatz U Keilholz 2008 Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial Lancet 372 117 126 10.1016/S0140-6736(08)61033-8 1:CAS:528:DC%2BD1cXosVynurk%3D 18620949 (Pubitemid 351952257)
21. CM Balch AC Buzaid SJ Soong MB Atkins N Cascinelli DG Coit ID Fleming JE Gershenwald A Houghton Jr JM Kirkwood KM McMasters MF Mihm DL Morton DS Reintgen MI Ross A Sober JA Thompson JF Thompson 2001 Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma J Clin Oncol 19 3635 3648 1:STN:280:DC%2BD3MvlvV2ktQ%3D%3D 11504745
22. SK Gupta P Glue S Jacobs D Belle M Affrime 2003 Single-dose pharmacokinetics and tolerability of pegylated interferon-alpha2b in young and elderly healthy subjects Br J Clin Pharmacol 56 131 134 10.1046/j.1365-2125. 2003.01836.x 1:CAS:528:DC%2BD3sXmvFSlsLo%3D 12848786 (Pubitemid 36886499)
23. JF Jen P Glue F Ezzet C Chung SK Gupta S Jacobs G Hajian 2001 Population pharmacokinetic analysis of pegylated interferon alfa-2b and interferon alfa-2b in patients with chronic hepatitis C Clin Pharmacol Ther 69 407 421 10.1067/mcp.2001.115872 1:CAS:528:DC%2BD3MXltFWlur0%3D 11406738 (Pubitemid 32554546)
24. S Gupta J Jen K Kolz D Cutler 2007 Dose selection and population pharmacokinetics of PEG-Intron in patients with chronic myelogenous leukaemia Br J Clin Pharmacol 63 292 299 10.1111/j.1365-2125.2006.02757.x 1:CAS:528:DC%2BD2sXkt1Wkt70%3D 16939523 (Pubitemid 46257068)
25. AM Eggermont S Suciu R MacKie W Ruka A Testori W Kruit CJ Punt M Delauney F Sales G Groenewegen DJ Ruiter I Jagiello K Stoitchkov U Keilholz D Lienard 2005 Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial Lancet 366 1189 1196 10.1016/S0140-6736(05)67482-X 1:CAS:528:DC%2BD2MXhtVGrsrbL 16198768 (Pubitemid 41393597)
26. G Alimena E Morra M Lazzarino AM Liberati E Montefusco D Inverardi P Bernasconi M Mancini E Donti F Grignani, et al. 1988 Interferon alpha-2b as therapy for Ph'-positive chronic myelogenous leukemia: a study of 82 patients treated with intermittent or daily administration Blood 72 642 647 1:STN:280:DyaL1c3psVehsA%3D%3D 3165298
27. HM Kantarjian S O'Brien P Anderlini M Talpaz 1996 Treatment of myelogenous leukemia: current status and investigational options Blood 87 3069 3081 1:CAS:528:DyaK28Xit1Kkurg%3D 8605319
28. F Guilhot C Chastang M Michallet A Guerci JL Harousseau F Maloisel R Bouabdallah D Guyotat N Cheron F Nicolini JF Abgrall J Tanzer 1997 Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group N Engl J Med 337 223 229 10.1056/NEJM199707243370402 1:CAS:528:DyaK2sXltlSktLc%3D 9227927 (Pubitemid 27310437)